New hope for hard-to-treat hepatitis c? small study tests triple therapy
NCT ID NCT01468584
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This study tested a new drug called MP-424 combined with two standard hepatitis C medicines (peginterferon alfa-2b and ribavirin) in 10 people with genotype 2 hepatitis C who had not responded to earlier treatment. The goal was to see if the virus could be cleared from the blood 24 weeks after treatment ended. The study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Minato-ku, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.